Can COVID-19 Be a Potential Risk Factor for Voriconazole-Induced Hyperkalemia?

Salma Ben Hmida 1 * , Ichrak Bougharriou 1, Hana Chaabouni 1, Hanen Ghozzi 2, Khaled Zghal 2, Mounir Benjemaa 1
More Detail
1 Infectious Diseases Department, Hedi Chaker Hospital, University of Sfax, TUNISIA
2 Pharmacology Department, University of Sfax, TUNISIA
* Corresponding Author
EUR J BASIC MED SCI, Volume 11, Issue 4, pp. 46-51. https://doi.org/10.21601/ejbms/11285
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

Voriconazole is an antifungal agent that is commonly used to treat fungal infections. Like any drug, it can cause side effects, especially in the case of overdose. Few cases of hyperkalemia have been reported, which presented when the serum voriconazole level was elevated or when there was voriconazole-drug interaction. We present here a case of voriconazole-induced hyperkalemia, prescribed for an oral candidiasis due to Candida glabrata in a patient hospitalized for severe COVID-19 pulmonary infection. Inflammation due to COVID-19 may play a role in the variability of voriconazole concentrations and then in hyperkalemia.
Keywords: COVID-19, candida glabrata, voriconazole, hyperkalemia

CITATION

Ben Hmida S, Bougharriou I, Chaabouni H, Ghozzi H, Zghal K, Benjemaa M. Can COVID-19 Be a Potential Risk Factor for Voriconazole-Induced Hyperkalemia?. EUR J BASIC MED SCI. 2021;11(4):46-51. https://doi.org/10.21601/ejbms/11285

REFERENCES

  • Tintillier M, Kirch L, Goffin E, Cuvelier C, Pochet J-M. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant. 2005; 20(3): 664-5. doi: 10.1093/ndt/gfh593.
  • Pawar P, Kashyap H, Malhotra S, Sindhu R. Hp--CD-Voriconazole in situ gelling system for ocular drug delivery: In vitro, stability, and antifungal activities assessment. BioMed research international. 2013; 2013: 341218. doi: 10.1155/2013/341218
  • Shi C, Xiao Y, Mao Y, Wu J, Lin N. Voriconazole: A review of population pharmacokinetic analyses. Clin Pharmacokinet. 2019; 58(6): 687-703. doi: 10.1007/s40262-019-00735-7
  • Nazmul MN, Miles CD, Westphal SG. Severe hyperkalemia complicating voriconazole treatment in a kidney transplant recipient with histoplasmosis: A case report. Transplant Proc. 2017; 49(10): 2372-3. doi: 10.1016/j.transproceed.2017.09.007.
  • Mikulska M, Novelli A, Aversa F, Cesaro S, de Rosa FG, Girmenia C, et al. Voriconazole in clinical practice. J Chemother. 2012; 24(6): 311-27. doi: 10.1179/1973947812Y.0000000051.
  • Malani AN, Kerr LE, Kauffman CA. Voriconazole: How to use this antifungal agent and what to expect. Semin Respir Crit Care Med. oct 2015; 36(5): 786-95. doi: 10.1055/s-0035-1562903.
  • Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis. 2004; 39(8): 1241-4. doi: 10.1086/424662.
  • Levine MT, Chandrasekar PH. Adverse effects of voriconazole: Over a decade of use. Clin Transplant. 2016; 30(11): 1377-86. doi: 10.1111/ctr.12834.
  • Choi J, Cho S, Kim G-H. Voriconazole-induced severe hyperkalemia precipitated by multiple drug interactions. Electrolytes & Blood Pressure. 2020; 18: 10. doi: 10.5049/EBP.2020.18.1.10.
  • Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, et al. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica. 2005; 35(6): 589-602. doi: 10.1080/00498250500158175.
  • Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am Coll Cardiol. 2016; 67(20): 2395-410. doi: 10.1016/j.jacc.2016.02.071.
  • Dalugama C, Pathirage M, Kularatne S a. M. Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report. J Med Case Rep. 2018; 12(1): 143. doi: 10.1186/s13256-018-1685-0.
  • van Wanrooy MJP, Span LFR, Rodgers MGG, van den Heuvel ER, Uges DRA, van der Werf TS, et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014; 58(12): 7098-101. doi: 10.1128/AAC.03820-14.
  • Yasu T, Konuma T, Kato S, Kurokawa Y, Takahashi S, Tojo A. Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients. Leuk Lymphoma. 2017; 58(11): 2731-3. doi: 10.1080/10428194.2017.1300897.
  • Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol. 2018; 9: 754. doi: 10.3389/fimmu.2018.00754.